Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Selected as "2017 China Innovative Medical Device Company"


Chongqing, China – On December 17, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was selected as "2017 China Innovative Medical Device Company" during the 10th China Pharmaceutical Strategy Summit 2017. MicroPort® Chief Operation Officer Glendy Wang accepted the award on behalf of the company and delivered a report of MicroPort®'s Innovation Path during the conference. Hosted by China National Pharmaceutical Industry Information Center, China Association of Pharmaceutical Commence, and Chongqing bio-pharmaceutical Industrial Park, the conference focused on the development trend of pharmaceuticals industry, covered topics related with "pharmaceuticals, device, medical service and online medical care" as well as released the list of "Index of Economic Operation of 2017 China Pharmaceuticals Industry" and the list of "2017 China Innovative Medical Device Company".
China Pharmaceutical Strategy Summit is a premier conference in China's pharmaceutical industry, which provides an open platform for domestic healthcare companies to exchange ideas on innovation achievements and innovation management annually. The list of "2017 China Innovative Medical Device Company" is made by China National Pharmaceutical Industry Information Center according to statistics of its database, annual statistical report of China Pharmaceutics and other official data. A total of 10 companies, including MicroPort®, were included in the list.
Since its establishment in 1998, MicroPort® has become a leading interventional medical device provider in China. It promotes the development and popularization of interventional treatment as well as the development of interdisciplines such as intelligent manufacturing, biological materials, and 3D printing. With over 200 products currently approved for use in over 5,000 hospitals worldwide, MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. MicroPort® was granted several national science and technology achievements awards and provincial-level honors. In the future, MicroPort® will continue to strive for innovation, improve product offering and company governance, and focus on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, and act as a role model to promote the development of China's high-end medical device industry.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Visits Baxiakeqi Village in Xinjiang for Charity Donation
[Next]:MicroPort® Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation